Drugs / OPOLIMOGENE CAPMILISBAC
OPOLIMOGENE CAPMILISBAC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02625857 | Dec 2015 → Jul 2018 | castration-resistant prostate carcinoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPOLIMOGENE CAPMILISBAC | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297242 ↗ |
| Known as | ADU-741 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297242 ↗ |
| Known as | JNJ-64041809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02625857 ↗ |
| Known as | JNJ-64041809; ADU-741 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297242 ↗ |
| Known as | Opolimogen capmilisbac | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297242 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT02625857 ↗ |